ASC41

ASC41 is a thyromimetic prodrug metabolized in the liver by CYP3A4 to an active form, ASC41-A, that is selective for thyroid hormone receptor beta. It is developed for non-alcoholic fatty liver disease.^[1] In 2023, Viking Therapeutics filed a lawsuit against ASC41's developer, Chinese company Ascletis BioScience, accusing it of stealing Viking's trade secrets to develop ASC41 which is allegedly similar to VK2809.^[2]

References[edit]

^ Fröhlich, Eleonore; Wahl, Richard (4 August 2022). "Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease". Metabolites. 12 (8): 718. doi:10.3390/metabo12080718. ISSN 2218-1989. PMC 9414490. PMID 36005590.
^ "Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache". Fierce Biotech. 3 January 2023. Retrieved 2 December 2023.

[1] Fröhlich, Eleonore; Wahl, Richard (4 August 2022). "Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease". Metabolites. 12 (8): 718. doi:10.3390/metabo12080718. ISSN 2218-1989. PMC 9414490. PMID 36005590.

[2] "Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache". Fierce Biotech. 3 January 2023. Retrieved 2 December 2023.

[1]

[2]